Laura Hogenboom

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.

Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.

Journal: Neurology

Published: July 29, 2026

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

Journal: European journal of neurology

Published: March 19, 2026

Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohorts.

Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohorts.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 20, 2026

Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.

Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: January 05, 2026

Author response to letter to the editor.

Author response to letter to the editor.

Journal: Journal of the neurological sciences

Published: December 19, 2025

Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.

Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.

Journal: Journal of the neurological sciences

Published: August 25, 2025

Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy.

Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy.

Journal: Scientific reports

Published: February 27, 2025

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 18, 2024

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: July 02, 2024

A personalized approach for anti-CD20 therapies in multiple sclerosis.

A personalized approach for anti-CD20 therapies in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: March 18, 2024

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.

Journal: Journal of neuroinflammation

Published: July 19, 2023

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: November 18, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026